Walgreens Boots Alliance Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Walgreens Boots Alliance kazanç ve gelirin sırasıyla yıllık 105.1% ve 1.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 111.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 12.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

105.1%

Kazanç büyüme oranı

111.2%

EPS büyüme oranı

Consumer Retailing kazanç büyümesi	6.8%
Gelir büyüme oranı	1.5%
Gelecekteki özkaynak getirisi	12.8%
Analist kapsamı	Good
Son güncelleme	19 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

LSE:0LSZ - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
8/31/2027	153,872	321	1,178	2,366	8
8/31/2026	151,657	-62	382	1,600	15
8/31/2025	148,963	-437	-334	1,027	16
8/31/2024	147,658	-8,636	-363	1,018	N/A
5/31/2024	145,533	-5,811	-894	725	N/A
2/29/2024	144,597	-6,037	-1,766	101	N/A
11/30/2023	142,406	574	-529	1,484	N/A
8/31/2023	139,081	-3,080	141	2,258	N/A
5/31/2023	136,108	-3,315	-821	1,305	N/A
2/28/2023	133,291	-3,144	982	2,954	N/A
11/30/2022	132,184	-2,964	1,403	3,293	N/A
8/31/2022	132,703	4,337	2,165	3,899	N/A
5/31/2022	134,516	5,111	3,439	5,058	N/A
2/28/2022	135,948	5,926	3,626	5,183	N/A
11/30/2021	134,972	5,965	4,057	5,459	N/A
8/31/2021	132,509	1,994	4,176	5,555	N/A
5/31/2021	128,617	1,972	4,983	6,396	N/A
2/28/2021	124,952	-926	4,195	5,556	N/A
11/30/2020	123,509	-981	4,200	5,618	N/A
8/31/2020	121,982	179	4,110	5,484	N/A
5/31/2020	125,566	519	4,359	5,777	N/A
2/29/2020	129,792	3,339	5,269	6,883	N/A
11/30/2019	132,984	3,628	4,576	6,195	N/A
8/31/2019	120,074	3,816	3,892	5,594	N/A
5/31/2019	136,354	4,817	4,402	6,032	N/A
2/28/2019	136,097	5,133	4,756	6,250	N/A
11/30/2018	134,590	5,326	6,261	7,720	N/A
8/31/2018	131,537	5,024	6,896	8,263	N/A
5/31/2018	128,244	4,314	N/A	7,460	N/A
2/28/2018	124,028	4,134	N/A	7,077	N/A
11/30/2017	120,453	3,845	N/A	7,729	N/A
8/31/2017	118,214	4,078	N/A	7,255	N/A
5/31/2017	116,701	4,306	N/A	7,895	N/A
2/28/2017	116,081	4,247	N/A	8,144	N/A
11/30/2016	116,819	4,117	N/A	7,640	N/A
8/31/2016	117,351	4,173	N/A	7,847	N/A
5/31/2016	117,237	3,169	N/A	6,694	N/A
2/29/2016	116,534	3,368	N/A	6,412	N/A
11/30/2015	112,923	4,480	N/A	5,365	N/A
8/31/2015	103,444	4,220	N/A	5,664	N/A
5/31/2015	93,979	3,973	N/A	5,543	N/A
2/28/2015	84,585	3,385	N/A	4,993	N/A
11/30/2014	77,617	2,059	N/A	4,791	N/A
8/31/2014	76,392	1,932	N/A	3,893	N/A
5/31/2014	75,276	2,810	N/A	3,632	N/A
2/28/2014	74,188	2,720	N/A	3,739	N/A
11/30/2013	73,230	2,760	N/A	3,833	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 0LSZ önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.1% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: 0LSZ önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: 0LSZ önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: 0LSZ şirketinin gelirinin (yıllık 1.5% ) UK pazarından (yıllık 3.5% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 0LSZ şirketinin gelirinin (yıllık 1.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 0LSZ 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 12.8 %).

Walgreens Boots Alliance Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2025

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Walgreens Boots Alliance, Inc. Provides Sales Guidance for Fiscal 2023

Recent updates

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on December 12, 2024

Walgreens Boots Alliance, Inc. Expects to Close Approximately 1,200 Stores over the Next 3 Years with About 500 Targeted to Close in Fiscal 2025

Full year 2024 earnings released: US$10.01 loss per share (vs US$3.57 loss in FY 2023)

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2025

Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

Saxena White P.A. Files New Securities Fraud Class Action Lawsuit Against Walgreens Boots Alliance, Inc. and Certain of its Executives

Walgreens Boots Alliance, Inc. to Report Q4, 2024 Results on Oct 15, 2024

Walgreens Announces Executive Appointments

Upcoming dividend of US$0.25 per share

Gross Law Firm Announces Lawsuit Against Walgreens Boots Alliance, Inc

Third quarter dividend of US$0.25 announced

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on September 12, 2024

Boots Chief Quits Reportedly After Walgreens' Sale Plan Stalls

Third quarter 2024 earnings released: EPS: US$0.40 (vs US$0.14 in 3Q 2023)

Walgreens Boots Alliance, Inc. to Report Q3, 2024 Results on Jun 27, 2024

Walgreens Announces Launch of Walgreens Brand Naloxone HCI Nasal Spray

Walgreens Reportedly Contacts Potential Buyers for £7 Billion Boots Drugstore Chain

Second quarter dividend of US$0.25 announced

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on June 12, 2024

Second quarter 2024 earnings released: US$6.85 loss per share (vs US$0.81 profit in 2Q 2023)

New major risk - Financial position

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Walgreens Boots Alliance, Inc. to Report Q2, 2024 Results on Mar 28, 2024

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

Walgreens Boots Alliance, Inc. Announces Executive Changes

Upcoming dividend of US$0.25 per share at 4.4% yield

High number of new directors

Walgreens Boots Alliance, Inc. Elects Robert L. Huffines to Board of Directors

Walgreens Reportedly Explores $4 Billion-Plus Sale of Shields Health

First quarter 2024 earnings released: US$0.078 loss per share (vs US$4.31 loss in 1Q 2023)

The Shareholder Commons, Inc Files a Notice of Exempt Solicitation to Walgreens Boots Alliance, Inc

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 25, 2024

Walgreens Boots Alliance, Inc. to Report Q1, 2024 Results on Jan 04, 2024

Walgreens Boots Alliance Names Neal Sample Executive Vice President and Chief Information Officer

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2023

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$3.57 loss per share (vs US$5.02 profit in FY 2022)

Walgreens Boots Alliance, Inc. Appoints Tim Wentworth as Chief Executive Officer, Effective October 23, 2023

Walgreens Boots Alliance, Inc.(NasdaqGS:WBA) dropped from S&P 100

Dicello Levitt Files Lawsuit Against Kenvue, Procter & Gamble, Glaxosmithkline, and Walgreens

Walgreens Boots Alliance, Inc. Announces CEO Changes

Upcoming dividend of US$0.48 per share at 6.6% yield

High number of new directors

Walgreens Boots Alliance, Inc. Announces Departure of James Kehoe as Executive Vice President

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on September 12, 2023

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire 120 pharmacies in Texas, Louisiana and Arkansas from Brookshire Grocery Company.

Third quarter 2023 earnings released: EPS: US$0.14 (vs US$0.33 in 3Q 2022)

An unknown buyer acquired 6.004471% stake in Option Care Health, Inc. (NasdaqGS:OPCH) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for approximately $330 million.

Walgreens Boots Alliance, Inc. to Report Q3, 2023 Results on Jun 27, 2023

Upcoming dividend of US$0.48 per share at 6.1% yield

CEO & Director recently bought US$340k worth of stock

Second quarter 2023 earnings released: EPS: US$0.81 (vs US$1.02 in 2Q 2022)

Upcoming dividend of US$0.48 per share at 5.2% yield

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on March 10, 2023

Walgreens Reportedly Weighs $2 Billion Sale of Pharmacy Automation Unit

Walgreens Boots Alliance, Inc. Provides Sales Guidance for Fiscal 2023

First quarter 2023 earnings released: US$4.31 loss per share (vs US$4.14 profit in 1Q 2022)

Walgreens Boots Alliance, Inc. to Report Q1, 2023 Results on Jan 05, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Independent Director recently sold US$661k worth of stock

Upcoming dividend of US$0.48 per share

Walgreens Boots Alliance, Inc. Announces Resignation of William Foote, the Board Lead Independent Director

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2022

Full year 2022 earnings released: EPS: US$5.02 (vs US$2.31 in FY 2021)

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into a definitive agreement to acquire remaining 45% stake in CareCentrix, Inc. for approximately $390 million.

John Standley to Leave as Executive Vice President of Walgreens Boots Alliance, Inc. on November 1, 2022

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire additional 30% stake in Shields Specialty Pharmacy Holdings, LLC from Welsh, Carson, Anderson & Stowe, Jack Shields & others for approximately $1.4 billion.

Walgreens Boots Alliance, Inc. to Report Q4, 2022 Results on Oct 13, 2022

Walgreens Boots Alliance, Inc. Announces Executive Appointments

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of a 55% stake in CareCentrix, Inc.

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of a 55% stake in CareCentrix, Inc.